On Friday, the government announced that Vinnova (Swedish Innovation Authority) will be commissioned in collaboration with NorthXBiologics (formerly Cobra Biologics) to establish an innovation hub in Matfors to enable the production of advanced drugs and vaccines.
- It feels fantastic fun.
We now have the opportunity to continue the expansion we started a couple of years ago, says Lars Fahlander, site manager at the facility in Matfors.
Matfors on the wallpaper
Läkemedelsfabriken changes its name from Cobra Biologics to NorthXBiologics after the Swedish investment company Flerie Invest, together with a group of investors, bought Cobra Biologics' operations in Matfors from American Charles River Laboratories for 455 million.
- We will need to hire more competent people to be able to take the next step in terms of process development and analysis development.
It also feels a bit cool when Matfors is mentioned in connection with Gothenburg and Uppsala, which was held at yesterday's press conference, says Lars Fahlander.
The business currently has 128 employees, all of whom are offered continued employment, according to Flerie Invest.
"Provides unique conditions" for the resort
"The establishment of NorthXBiologics is positive for Sweden and Swedish competitiveness and provides a unique opportunity to attract skills and more high-quality jobs to Matfors," says Minister of Trade and Industry Ibrahim Baylan in a press release.
Vinnova will receive SEK 21 million in 2021 for the assignment, and an estimated SEK 15 million will be set aside in 2022.
Vinnova will also contribute SEK 14 million from existing funds, according to the government.